January 16, 2017 3:41 PM ET

Biotechnology

Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease and raised transaminases, as well as for the treatment of patients with severe alcoholic hepatitis. The company was founded in 2005 and is headquartered in San ...

16745 West Bernardo Drive

Suite 200

San Diego, CA 92127

United States

Founded in 2005

25 Employees

Phone:

858-376-2600

Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $473.8K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 58
Total Annual Compensation: $373.6K
Co-Founder, Chief Financial Officer, Senior Vice President of Finance and Secretary
Age: 65
Total Annual Compensation: $302.6K
Compensation as of Fiscal Year 2015.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. - Special Call

To discuss the collaboration and license agreement and update the emricasan development program

Conatus Pharmaceuticals Inc. Announces Board Changes

On December 19, 2016, Shahzad Malik, M.D. resigned from the Board of Directors of Conatus. In connection with this resignation, pursuant to Conatus' bylaws, the Board voted to decrease the size of the Board from seven to six members. The Board appointed James Scopa as the chair of the Audit Committee to replace Dr. Malik as the Audit Committee chair. The Board also determined that Mr. Scopa qualifies as an audit committee financial expert" as that phrase is defined under the regulations promulgated by the SEC. Further, the Board appointed Daniel L. Kisner, M.D. as a member of the Audit Committee.

Conatus Pharmaceuticals Inc. Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan with Novartis

Conatus Pharmaceuticals Inc. announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis. Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Furthermore, Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors. In addition, Novartis will pay 50% of Conatus’ Phase 2b emricasan development costs after the option exercise, including the planned ENCORE-LF trial in decompensated NASH cirrhosis which, under the current development plan consistent with recent regulatory agency recommendations, will be conducted as Phase 2b rather than Phase 2b/3. Phase 2b emricasan development costs also encompass the ongoing ENCORE-PH trial in primarily compensated NASH cirrhosis, POLT-HCV-SVR trial in post-transplant HCV fibrosis and cirrhosis, and ENCORE-NF trial in NASH fibrosis. Novartis will assume full responsibility for emricasan’s Phase 3 development and all combination product development.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 19, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Conatus Pharmaceuticals Inc., please visit www.conatuspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.